About Premie BiliRecs


Premie BiliRecs (PBR) was created to provide clinical decision support for the treatment of indirect hyperbilirubinemia in pre-term neonates from 27 weeks and 0 days through 34 weeks and 6 days post-menstrual age. Though there is limited evidence on phototherapy and exchange transfusion thresholds for this age group, PBR serves to operationalize the expert recommendations published by Maisels et al. in 2012. Because phototherapy and exchange transfusion thresholds are lower at early chronologic age, the tool is intended for use only in infants greater than 48 hours of age. Ultimately, professional clinical judgement should guide the management of indirect hyperbilirubinemia in all preterm neonates.


Peer-reviewed journal articles:

Clinical decision support tool for phototherapy initiation in preterm infants
Arain YH, Banda JM, Faulkenberry JH, Bhutani VK, and Palma JP
Journal of Perinatology August 2020

Development of a Web-Based Decision Support Tool to Operationalize and Optimize Management of Hyperbilirubinemia in Preterm Infants
Palma JP, Arain YH
Clin Perinatol March 2016

An approach to the management of hyperbilirubinemia in the preterm infant less than 35 weeks of gestation
Maisels MJ, Watchko JF, Bhutani VK, and Stevenson DK
Journal of Perinatology June 2012

Jaundice and kernicterus in the moderately preterm infant
Wallenstein MW, Bhutani VK
Clinics in Perinatology December 2013

Clinical Practice Guideline: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation
AAP Subcommittee on Hyperbilirubinemia
Pediatrics July 2004

Created By

Clinical Associate Professor, Neonatal and Developmental Medicine Stanford University
Assistant Clinical Professor, Neonatology University of California San Diego
Senior Application Architect Stanford Children's Health
Clinical Professor, Neonatal and Developmental Medicine Stanford University